Log in to save to my catalogue

Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant

Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8908811

Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant

Publication information

Publisher

United States: Massachusetts Medical Society

More information

Scope and Contents

Contents

In a large case–control study in England, immunity to the omicron variant was very low and less than that to the delta variant 20 weeks after the second vaccine dose, regardless of the initial vaccine type. A booster dose of one of the mRNA vaccines improved efficacy to approximately 65 to 70%, but protection waned over a 10-week period.

Alternative Titles

Full title

Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8908811

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8908811

Other Identifiers

ISSN

0028-4793

E-ISSN

1533-4406

DOI

10.1056/NEJMoa2119451

How to access this item